29 April,2021 06:36 PM IST | New Delhi | PTI
Pic/AFP
Bharat Biotech on Thursday announced a cut in price of its COVID-19 vaccine ''Covaxin'' it plans to sell to the states to Rs 400 per dose from the earlier Rs 600.
This follows a widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.
"Recognising the enormous challenges in the public healthcare system, we have made Covaxin available to state governments at a price of 400/ dose", Bharat Biotech said in its announcement.
The company is deeply concerned with the critical pandemic circumstances that India is facing at this time, it added.
ALSO READ
Trump chooses anti-vaccine activist Robert F. Kennedy Jr. as health secretary
Trump expected to choose vaccine skeptic Robert F. Kennedy Jr. as health secretary: AP sources
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen
MVA promises caste census, free cervical cancer vaccine for girls; Rs 3,000 a month to women
Maharashtra polls: MVA promises caste census, free cervical cancer vaccine for minor girls
Serum Institute of India (SII) had on Wednesday slashed the price of its COVID-19 vaccine ''Covishield'' to Rs 300 per dose from the earlier Rs 400 for state governments.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
